The Advanced Biotechnology Projects Roadshow, newly introduced at the 10th China Pharmaceutical Innovation and Investment Conference (CBIIC), was successfully held on October 27. Co-organized by the National Biopharmaceutical Regional Technology Transfer and Transformation Center (Jiangsu, Nanjing), the session aimed to empower the commercialization of innovative scientific achievements and accelerate precise matchmaking between technology and capital, thereby establishing an efficient communication platform bridging innovation and investment in the biotechnology industry.

During the one-day event, 20 outstanding projects from diverse fields were presented, ranging from breakthrough therapies addressing unmet clinical needs to disruptive technology platforms reshaping traditional R&D paradigms, comprehensively showcasing cutting-edge exploration and practical achievements in biotechnology.

YANG Yehui, Assistant to the President of Huajin Securities/Head of Research Institute of HuaJin Securities, and ZHENG Yu, Senior Pharmaceutical Researcher and Analyst, Guolian Minsheng Securities Research Institute, served as moderators of the session.

In the field of oncology, multiple innovative drugs and therapies demonstrated distinct characteristics of precision and synergy.

The PDC drug LB001, developed by the team led by LU Weiyue, Director of State Key Laboratory of Overcoming the Drug Delivery Barrier with Advanced Formulations, Fudan University, provides a novel therapeutic pathway for glioma, a highly challenging malignancy. Nanjing Diligene Biotechnology has successfully established two core technology platforms; one of its key pipelines, the ADC drug BP-A102, has demonstrated strong antitumor activity in vitro and in PDX models and has entered the CMC and GLP toxicology stage. In addition, Wuhan Binhui Biopharmaceutical’s oncolytic virus (oHSV2) product OH2 injection, Prolium Biosciences’ next-generation CLDN6 ADC and dual-payload ADC, and Tide Pharmaceutical’s SHP2 degrader TRD209 for malignant tumors have each provided new approaches to overcoming current bottlenecks in oncology treatment through innovations in targets, drug design, and mechanisms of action.

In the fields of gene editing and cell therapy, “safety, universality, and accessibility” have become key themes of technological advancement.

CorrectSequence Therapeutics has established China’s first proprietary single-base editing drug R&D and translation platform based on its original transformer base editor (tBE) technology. Projects from BRL Medicine, including gene editing therapies for β-thalassemia, non-viral PD-1 targeted integration CAR-T, and UCAR-T, have demonstrated promising clinical outcomes. Meanwhile, Xianbo Biotech focuses on universal cell therapy and breakthroughs in solid tumors, deploying cutting-edge technologies to deliver more accessible and effective next-generation universal cell therapies.

In the field of AI- and brain-inspired intelligence-driven drug discovery, “efficiency, precision, and full-chain enablement” define the core competitiveness of technology platforms.

Clickmab Biotech has developed the world’s first validated epitope-specific AI antibody de novo design platform, capable of generating quantifiable outputs tailored to specific target proteins, starting molecules, and optimization directions. Cambrian Neuro Science’s brain-like neural networks (BNNs) combined with AI accelerate the identification of CNS drug candidates. SigmaHit, developed by Beijing Saimingqiang, is currently the only known structure-based platform in drug discovery capable of screening trillions of compounds, enabling efficient targeted design and screening.

For common diseases and public health challenges such as allergic conditions, asthma, and COVID-19, several innovative therapies highlighted advances in mechanism innovation and formulation optimization.

Anhui Genebio Biotech’s blocking antibody targeting the IgE-FcεRI pathway is expected to achieve breakthroughs in efficacy and safety, enabling longer dosing intervals and higher symptom relief rates. Hangzhou Chance Pharmaceuticals has developed the inhaled TSLP-targeting nanobody dry powder CXX168 using its proprietary VFC platform and spray-drying technology, offering smaller molecular size and improved permeability. SNS812, developed by Zhongtian (Shanghai) Biotech, is an innovative broad-spectrum inhalable siRNA therapy for COVID-19 and the first of its kind globally to receive U.S. FDA approval to enter clinical trials.

In addition, the Roadshow Session featured a number of innovative projects spanning theranostics, metabolic disease treatment, and immunomodulation.

Projects such as Shanxi Nanolattix Biotech’s theranostic antibody-drug conjugate radiopharmaceutical (RDC), developed based on its proprietary BioLattix platform, have established a full-chain R&D system from target discovery to clinical trials, with its core product RT01 entering the clinical translation stage. Shanghai Kejun Pharma has developed the world’s first anti-platelet drug CG-0255, featuring both injectable and oral formulations, based on its proprietary “Puyu” AI prodrug platform, while its THR-β agonist CG-0416 is expected to become the world’s first non-GLP-1 oral weight-loss prodrug. Meanwhile, Shenzhen Aixin Dawei’s small-molecule targeted conjugation technology, Biofase Biotech’s three innovation platforms based on biomolecular condensates/phase separation, TJ Biopharma’s IG+ antibody platform driving innovation in oncology and autoimmune diseases, and Nanjing Geneleap Biotech’s off-the-shelf in situ therapeutic tumor vaccine collectively demonstrate the diversity and vast potential of innovation in the biopharmaceutical industry.

As a strategic emerging industry, biotechnology’s innovation breakthroughs and industrial transformation not only represent a vivid response to national priorities but also serve as a critical pathway to achieving global technological leadership and fostering new quality productive forces. The successful convening of the Advanced Biotechnology Projects Roadshow not only provided a comprehensive showcase of current innovation achievements in biotechnology but also created an important opportunity to accelerate technological breakthroughs and industrial application.

Looking ahead, as these innovative projects continue to advance and translate into real-world applications, more breakthrough technologies are expected to enter clinical practice and benefit patients. This will not only propel China’s biopharmaceutical industry from a follower to a global leader but also contribute Chinese wisdom and strength to the high-quality development of the global biopharmaceutical industry, exemplifying the role of technological innovation in advancing Chinese modernization.